Latest Conference Articles

New phase 2 data from the KARE study presented at AAD found that the therapy improved itch severity and sleep in patients with atopic dermatitis and pruritis.

Dr. Raj Chovatiya provides updates from AAD on some pending and potential FDA approvals for several dermatology therapies.

With no approved therapies currently available, Dr. Brett King feels that the JAK inhibitor baricitinib could provide patients with a long sought after solution to hair loss.

New AAD 2022 data show the novel gene therapy from Krystal Biotech provided wound healing by 3 months in patients with dystrophic epidermolysis bullosa.

Dr. Gil Yosipovitch suspects that dupilumab will be approved for use in patients with prurigo nodularis based on new data from the LIBERTY-RN PRIME2 trial.

The Feinberg School of Medicine expert discusses the impact of dupilumab and other biologics on severely affected children and adolescnets.

An expert delves into the increased risk of conditions including psoriasis flares, lupus, and scleroderma following COVID-19.

New phase 4 data suggests that apremilast could be used to improve cardiometabolic function in patients with psoriatic disease.

Data from the 5-year extension trial ECZTEND indicated that the overall safety profile of tralokinumab was consistent with the previous ECZTRA trials.

International investigators observe differing levels of severe COVID-19 risk for patients with atopic dermatitis, dependent on their current therapy.

Data from the phase 3 TRuE-V clinical program show the topical JAK inhibitor provided substantial repigmentation to more than half of treated patients.

Data from a pair of phase 3 trials concluded that oral baricitinib was superior to placebo for patients with severe alopecia areata for hair regrowth at 36 weeks.

A Perelman School of Medicine assessment of biopsy rates support previous findings showing that dermatologists are less confident making psoriasis diagnoses in patients with darker skin color.

John E. Harris, MD, PhD, discusses the delayed decision date for the topical JAK inhibitor, and what more needs to be researched on the drug.

New data suggest that treatment with dupilumab does not increase the risk of COVID-19 infection in patients with atopic diseases.

John E. Harris, MD, PhD, explains how JAK inhibitors and biologic therapy may advance the field from "Iron Age" era treatment strategy.

The increased risk of cancer development in patients with atopic dermatitis has been suggested due to chronic inflammation or immunologic defects inherent to the disease and various treatments.

New AAD 2022 pooled analysis show the PDE-4 inhibitor topical therapy provides tolerable and effective improvement at 8 weeks.

Those who are underweight or normal weight were more likely to have an IgE mediated food allergy.

Gestational age and NICU admission both were associated with the risk of developing EoE.

The algorithm also resulted in a large reduction in oral food challenges.

Additionally, the association between atopic dermatitis and sensitization to eggs was more common during the pandemic then in years prior.

By blocking certain neurogenic changes that occur in the lungs at childhood, patients may avoid asthma and allergic responses into adulthood.

Investigators examined data on abrocitinib from the JADE REGIMEN study.

Currently, antibiotics comprise roughly 80% of prescribed pregnancy medications, and recent epidemiological studies have indicated a link between antibiotic use and dysbiosis.

Dr. Mathias noted that investigators are continuing to determine if age plays a role in peanut allergy risk and sensitization.

Itch intensity was highest at bedtime compared to all other time periods of the day.

This decision could further exacerbate health inequities among populations that are socioeconomically disadvantaged.